Flamel Seeks To Block Generic Coreg

Law360, New York (September 9, 2011, 8:53 PM EDT) -- Flamel Technologies SA hit Anchen Pharmaceuticals Inc. with a patent suit Friday, alleging the drug manufacturer infringed a patent for Flamel's heart failure drug Coreg when it submitted a bid to produce a generic version.

According to the complaint filed in Maryland federal court, Flamel, a drugmaker based in France, was informed in July that Anchen had asked the U.S. Food and Drug Administration for approval to develop a generic version of a 40-milliliter carvedilol phosphate capsule, using the active ingredient in Flamel's Coreg.

The patent-in-suit...
To view the full article, register now.